市場調査レポート

商品コード

1206503

中東・アフリカの過活動膀胱治療市場の2028年までの予測- 地域別分析- 薬物療法別、疾患タイプ別

Middle East & Africa Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy and Disease Type

出版日: 2023年01月24日 | 発行: The Insight Partners

| ページ情報: 英文 134 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 3,000 471,420円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 4,000 628,560円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 5,000 785,700円

レポートPDFを企業内すべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

中東・アフリカの過活動膀胱治療市場は、2022年の2億9,094万米ドルから2028年には3億3,017万米ドルに成長すると予測、2022年から2028年までのCAGRは2.1%と推定。

中東・アフリカの過活動膀胱治療市場は、今後M&Aの増加で活性化する

企業はM&Aを通じて、新市場への参入や新技術の獲得により競争力を高めることができます。過活動膀胱治療市場で進行中のM&Aは、さまざまな企業に成長機会をもたらしています。2021年7月、ウロメディカルは、過活動膀胱の治療に特化したワイヤレス給電、注射可能なマイクロテクノロジー神経刺激装置を提供するマイクロンメディカルを買収し、泌尿器科のポートフォリオを強化しました。患者の日常生活に簡単に取り入れることができるこれらの神経刺激装置は、便利で安全、低侵襲で費用対効果の高い泌尿器科治療の選択肢を提供します。2021年2月、医療技術会社であるAxonics Modulation Technologies, Inc.は、Contura Ltd.とその独自製品であるストレス性尿失禁（SUI）女性用尿道増量剤Bulkamidを買収しました。アクソニックスは、排尿・排便障害治療用の新しい埋め込み型仙骨神経調節（SNM）デバイスを製造・販売しています。Contura Ltd.の買収は、SNM事業を世界的に拡大し、非常に未開拓な大規模なSUI市場に対応する機会を提供するものです。同社は、泌尿器科医や泌尿器科医が患者を治療するために、臨床的に差別化された失禁ソリューション一式を提供することを計画しています。このように、合併・買収の増加が中東・アフリカの過活動膀胱治療市場の成長を後押ししています。

中東・アフリカの過活動膀胱治療市場の概要

中東・アフリカの過活動膀胱治療市場は、UAE、サウジアラビア、南アフリカ、その他中東・アフリカに区分されます。市場成長の背景には、慢性疾患の有病率の増加や、同地域における医学的調査研究の増加があります。尿失禁は、サウジアラビアでは女性の間で多く見られる臨床症状です。National Library of Medicineに掲載されたThe Cureus Journal of Medical Scienceによると、2022年、サウジアラビアのJeddahとRiyadhにおける尿失禁の有病率はそれぞれ41.4%と29%と推定されました。年齢、肥満、内科的併存疾患、子宮摘出、多胎などのいくつかの要因が、尿失禁状態の発生に寄与していると言われています。さらに、多胎妊娠や老年人口の増加も、過活動膀胱治療市場の成長に寄与するいくつかの要因となっています。また、慢性疾患の増加や、迅速な診断、効果的な治療法、予防策に対する高いニーズが、サウジアラビアでの市場成長を後押ししています。サウジアラビア保健省は、2,259のセンターを通じて、～13,455人の人々にプライマリーヘルスサービスを提供しています。一次医療センターは、泌尿器科関連の問題など、新たな訴えに対処するための最初の窓口です。本製品は、プライマリーヘルスセンターの医師が観察する一般的な泌尿器科疾患に関する知識と実践パターンを評価するのに役立ちます。このように、前述の要因は、今後数年間における過活動膀胱治療市場の成長を促進すると予想されています。

中東・アフリカ過活動膀胱治療市場の収益と2028年までの予測

中東・アフリカの過活動膀胱治療市場のセグメンテーション

中東・アフリカの過活動膀胱治療市場は、薬物療法、疾患タイプ、国別に区分されます。

薬物療法に基づき、中東・アフリカの過活動膀胱治療市場は、抗コリン薬、ミラベグロン、ボトックス、神経刺激、膀胱内注入に区分されます。2022年の市場では、ミラベグロンセグメントが最大のシェアを登録しました。

疾患タイプに基づき、中東・アフリカの過活動膀胱治療市場は特発性過活動膀胱と神経原性膀胱に二分されます。2022年の市場では、特発性過活動膀胱分野がより大きなシェアを占めています。

国別に見ると、中東・アフリカの過活動膀胱治療市場は、サウジアラビア、南アフリカ、UAE、その他中東・アフリカに分類されます。2022年はサウジアラビアが市場を独占しました。

AbbVie Inc、Alembic Pharmaceuticals Limited、Astellas Pharma Inc、Endo Pharmaceuticals Inc、Hisamitsu Pharmaceutical Co., Inc.、Medtronic Plc、Pfizer Inc、Teva Pharmaceutical Industries Ltdが中東・アフリカの過活動膀胱治療市場で事業を展開している主要企業です。

List Of Tables

Table 1. UAE Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 2. UAE Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 3. UAE Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 4. UAE Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 5. Saudi Arabia Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 6. Saudi Arabia Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 7. Saudi Arabia Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 8. Saudi Arabia Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 9. South Africa Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 10. South Africa Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 11. South Africa Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 12. South Africa Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 13. Rest of MEA Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 14. Rest of MEA Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 15. Rest of MEA Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 16. Rest of MEA Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 17. Organic Developments Done by Companies
Table 18. Glossary of Terms

List Of Figures

Figure 1. MEA Overactive Bladder Treatment Market Segmentation
Figure 2. MEA Overactive Bladder Treatment Market Segmentation, By Country
Figure 3. MEA Overactive Bladder Treatment Market Overview
Figure 4. Mirabegron Segment Held Largest Share by Pharmacotherapy in MEA Overactive Bladder Treatment market
Figure 5. South Africa Is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. MEA: PEST Analysis
Figure 7. MEA Overactive Bladder Treatment Market: Impact Analysis of Driver and Restraints
Figure 8. MEA Overactive Bladder Treatment Market - Revenue Forecast and Analysis - 2019- 2028
Figure 9. MEA Overactive Bladder Treatment Market, by Pharmacotherapy 2021 & 2028 (%)
Figure 10. Mirabegron: MEA Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 11. Botox: MEA Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Neurostimulation: MEA Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Transcutaneous Sacral Nerve Stimulation: MEA Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Transcutaneous Tibial Nerve Stimulation: MEA Overactive Bladder Market Revenue and Forecasts to 2028 (US$ MN)
Figure 15. Percutaneous Posterior Tibial Nerve: MEA Overactive Bladder Stimulation Market Revenue and Forecasts To 2028 (US$ MN)
Figure 16. Others: MEA Overactive Bladder Market Revenue and Forecasts To 2028 (US$ MN)
Figure 17. Anticholinergics: MEA Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Solifenacin: MEA Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Oxybutynin: MEA Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Fesoterodine: MEA Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Darifenacin: MEA Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Tolterodine: MEA Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 23. Trospium: MEA Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Other Anticholinergics: MEA Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. Intravesical Instillation: MEA Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 26. MEA Overactive Bladder Treatment Market, by Disease Type 2021 & 2028 (%)
Figure 27. Idiopathic: MEA Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Neurogenic: Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. MEA: Overactive Bladder Treatment Market, by Key Country - Revenue (2021) (US$ Million)
Figure 30. UAE: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 31. Saudi Arabia: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. South Africa: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Rest of MEA: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)

Product Code: BMIRE00027936

The Middle East & Africa overactive bladder treatment market is expected to grow from US$ 290.94 million in 2022 to US$ 330.17 million by 2028; it is estimated to grow at a CAGR of 2.1% from 2022 to 2028.

Increasing Number of Mergers and Acquisitions to Fuel Middle East & Africa Overactive Bladder Treatment Market in Coming Years

Through mergers and acquisitions (M&A), companies can gain a competitive edge by entering new markets and acquiring new technologies. The ongoing mergers and acquisitions in the overactive bladder treatment market are creating growth opportunities for various companies. In July 2021, Uro Medical strengthened its urology portfolio with the acquisition of Micron Medical, which offers wirelessly powered, injectable, microtechnology neurostimulators focused on treating overactive bladder. These neurostimulators, which can be easily incorporated into patients' daily lives, offer a convenient, safe, minimally invasive, and cost-effective urological treatment option. In February 2021, Axonics Modulation Technologies, Inc.-a medical technology company-acquired Contura Ltd. and its proprietary product, Bulkamid, which is a urethral bulking agent for women with stress urinary incontinence (SUI). Axonics produces and markets novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction. The acquisition of Contura Ltd. provides an opportunity to expand its SNM business across the world and serve the large, highly underpenetrated SUI market. The company plans to offer urogynecologists and urologists a complete suite of clinically differentiated incontinence solutions to treat their patients. Thus, increasing number of mergers and acquisitions is propelling Middle East & Africa overactive bladder treatment market growth.

Middle East & Africa Overactive Bladder Treatment Market Overview

The Middle East & Africa overactive bladder treatment market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The market growth is attributed to the increasing prevalence of chronic diseases and growing medical research studies across the region. Urinary incontinence is a clinical condition that is observed more among women in Saudi Arabia. According to The Cureus Journal of Medical Science published in the National Library of Medicine, in 2022, the prevalence of urinary continence in Jeddah and Riyadh, Saudi Arabia, was estimated to be 41.4% and 29%, respectively. A few factors such as age, obesity, medical comorbidities, hysterectomy, and multiparity contribute to the occurrence of urinary incontinence condition. Further, multiple pregnancy cases and rise in the geriatric population are also a few factors contributing to the growth of the overactive bladder treatment market. Also, the rise in the prevalence of chronic diseases and the high demand for rapid diagnosis, effective treatment options, and preventive measures are boosting the market growth in Saudi Arabia. The Saudi Arabia Ministry of Health provides primary health services through 2,259 centers to ~13,455 people. The primary health center settings are the first in line that deals with emerging complaints such as urological-related problems. It helps assess knowledge and practice patterns regarding common urological problems observed by primary health centers physicians. Thus, aforementioned factors are anticipated to fuel the growth of the overactive bladder treatment market in the coming years.

Middle East & Africa Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Overactive Bladder Treatment Market Segmentation

The Middle East & Africa overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.

Based on pharmacotherapy, the Middle East & Africa overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022.

Based on disease type, the Middle East & Africa overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.

Based on country, the Middle East & Africa overactive bladder treatment market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022.

AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Middle East & Africa overactive bladder treatment market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East & Africa overactive bladder treatment market
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa overactive bladder treatment market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the overactive bladder treatment market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 MEA Overactive Bladder Treatment Market- By Pharmacotherapy
- 1.3.2 MEA Overactive Bladder Treatment Market- By Disease Type
- 1.3.3 MEA Overactive Bladder Treatment Market - By Country

2. MEA Overactive Bladder Treatment Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. MEA Overactive Bladder Treatment Market - Market Landscape

4.1 Overview
4.2 MEA PEST Analysis
4.3 Expert Opinion

5. MEA Overactive Bladder Treatment Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increase in Prevalence of Urinary Incontinence
- 5.1.2 Growing Incidence of Urinary Tract Infections
5.2 Key Market Restraints
- 5.2.1 Recalls of Therapeutic Drugs
5.3 Key Market Opportunities
- 5.3.1 Increasing Number of Mergers and Acquisitions
5.4 Future Trends
- 5.4.1 Robust Pipeline of Drugs and Successive Launch of Novel Therapies
5.5 Impact analysis

6. MEA Overactive Bladder Treatment Market - MEA Analysis

6.1 MEA Overactive Bladder Treatment Market Revenue Forecast and Analysis

7. MEA Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy

7.1 Overview
7.2 MEA Overactive Bladder Treatment Market, By Pharmacotherapy 2021 & 2028 (%)
7.3 Mirabegron
- 7.3.1 Overview
- 7.3.2 Mirabegron: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.4 Botox
- 7.4.1 Overview
- 7.4.2 Botox: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.5 Neurostimulation
- 7.5.1 Overview
- 7.5.2 Neurostimulation: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.3 Transcutaneous Sacral Nerve Stimulation
  - 7.5.3.1 Overview
  - 7.5.3.2 Transcutaneous Sacral Nerve Stimulation: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.4 Transcutaneous Tibial Nerve Stimulation
  - 7.5.4.1 Overview
  - 7.5.4.2 Transcutaneous Tibial Nerve Stimulation: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.5 Percutaneous Posterior Tibial Nerve Stimulation
  - 7.5.5.1 Overview
  - 7.5.5.2 Percutaneous Posterior Tibial Nerve Stimulation: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.6 Others
  - 7.5.6.1 Overview
  - 7.5.6.2 Others: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Anticholinergics
- 7.6.1 Overview
- 7.6.2 Anticholinergics: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.3 Solifenacin
  - 7.6.3.1 Overview
  - 7.6.3.2 Solifenacin: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.4 Oxybutynin
  - 7.6.4.1 Overview
  - 7.6.4.2 Oxybutynin: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.5 Fesoterodine
  - 7.6.5.1 Overview
  - 7.6.5.2 Fesoterodine: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.6 Darifenacin
  - 7.6.6.1 Overview
  - 7.6.6.2 Darifenacin: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.7 Tolterodine
  - 7.6.7.1 Overview
  - 7.6.7.2 Tolterodine: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.8 Trospium
  - 7.6.8.1 Overview
  - 7.6.8.2 Trospium: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.9 Other Anticholinergics
  - 7.6.9.1 Overview
  - 7.6.9.2 Other Anticholinergics: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.7 Intravesical Instillation
- 7.7.1 Overview
- 7.7.2 Intravesical Instillation: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)

8. MEA Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type

8.1 Overview
8.2 MEA Overactive Bladder Treatment Market, By Disease Type 2021 & 2028 (%)
8.3 Idiopathic Overactive Bladder
- 8.3.1 Overview
- 8.3.2 Idiopathic: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Neurogenic Overactive Bladder
- 8.4.1 Overview
- 8.4.2 Neurogenic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)

9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis

9.1 Overview
- 9.1.1 MEA: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
  - 9.1.1.1 UAE: overactive bladder treatment Market - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.1.1 UAE: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.1.2 UAE: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.1.2.1 UAE: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.1.2.2 UAE Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.1.3 UAE: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
  - 9.1.1.2 Saudi Arabia: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.2.1 Saudi Arabia: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.2.2 Saudi Arabia: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.2.2.1 Saudi Arabia: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.2.2.2 Saudi Arabia Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.2.3 Saudi Arabia: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
  - 9.1.1.3 South Africa: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.3.1 South Africa: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.3.2 South Africa: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.3.2.1 South Africa: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.3.2.2 South Africa Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.3.3 South Africa: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
  - 9.1.1.4 Rest of MEA: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.4.1 Rest of MEA: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.4.2 Rest of MEA: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.4.2.1 Rest of MEA: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.4.2.2 Rest of MEA Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.4.3 Rest of MEA: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)

10. Overactive Bladder Treatment Market- Industry Landscape

10.1 Overview
10.2 Organic Developments
- 10.2.1 Overview

11. Company Profiles

11.1 Alembic Pharmaceuticals Limited
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Astellas Pharma Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 AbbVie Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Teva Pharmaceutical Industries Ltd
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Endo Pharmaceuticals Inc.
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co., Inc.
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Medtronic Plc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Pfizer Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms

中東・アフリカの過活動膀胱治療市場の2028年までの予測- 地域別分析- 薬物療法別、疾患タイプ別

Middle East & Africa Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy and Disease Type

目次

第1章イントロダクション

第2章中東・アフリカの過活動膀胱治療市場- 主要な要点

第3章調査手法

第4章中東・アフリカの過活動膀胱治療市場- 市場情勢

第5章中東・アフリカの過活動膀胱治療市場- 主要市場力学

第6章中東・アフリカの過活動膀胱治療市場- 中東・アフリカ分析

第7章中東・アフリカの過活動膀胱治療市場分析と2028年までの予測- 薬物療法別

第8章中東・アフリカの過活動膀胱治療市場の分析と2028年までの予測- 疾患タイプ別

第9章過活動膀胱治療薬市場の収益と2028年までの予測- 国別分析

第10章過活動膀胱治療市場-業界情勢

第11章企業プロファイル

第12章付録

List Of Tables

List Of Figures

Reasons to Buy:

Table Of Contents

1. Introduction

2. MEA Overactive Bladder Treatment Market - Key Takeaways

3. Research Methodology

4. MEA Overactive Bladder Treatment Market - Market Landscape

5. MEA Overactive Bladder Treatment Market - Key Market Dynamics

6. MEA Overactive Bladder Treatment Market - MEA Analysis

7. MEA Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy

8. MEA Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type

9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis

10. Overactive Bladder Treatment Market- Industry Landscape

11. Company Profiles

12. Appendix

中東・アフリカの過活動膀胱治療市場の2028年までの予測- 地域別分析- 薬物療法別、疾患タイプ別

Middle East & Africa Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy and Disease Type

目次

第1章 イントロダクション

第2章 中東・アフリカの過活動膀胱治療市場- 主要な要点

第3章 調査手法

第4章 中東・アフリカの過活動膀胱治療市場- 市場情勢

第5章 中東・アフリカの過活動膀胱治療市場- 主要市場力学

第6章 中東・アフリカの過活動膀胱治療市場- 中東・アフリカ分析

第7章 中東・アフリカの過活動膀胱治療市場分析と2028年までの予測- 薬物療法別

第8章 中東・アフリカの過活動膀胱治療市場の分析と2028年までの予測- 疾患タイプ別

第9章 過活動膀胱治療薬市場の収益と2028年までの予測- 国別分析

第10章 過活動膀胱治療市場-業界情勢

第11章 企業プロファイル

第12章 付録

List Of Tables

List Of Figures

Reasons to Buy:

Table Of Contents

1. Introduction

2. MEA Overactive Bladder Treatment Market - Key Takeaways

3. Research Methodology

4. MEA Overactive Bladder Treatment Market - Market Landscape

5. MEA Overactive Bladder Treatment Market - Key Market Dynamics

6. MEA Overactive Bladder Treatment Market - MEA Analysis

7. MEA Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy

8. MEA Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type

9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis

10. Overactive Bladder Treatment Market- Industry Landscape

11. Company Profiles

12. Appendix

第1章イントロダクション

第2章中東・アフリカの過活動膀胱治療市場- 主要な要点

第3章調査手法

第4章中東・アフリカの過活動膀胱治療市場- 市場情勢

第5章中東・アフリカの過活動膀胱治療市場- 主要市場力学

第6章中東・アフリカの過活動膀胱治療市場- 中東・アフリカ分析

第7章中東・アフリカの過活動膀胱治療市場分析と2028年までの予測- 薬物療法別

第8章中東・アフリカの過活動膀胱治療市場の分析と2028年までの予測- 疾患タイプ別

第9章過活動膀胱治療薬市場の収益と2028年までの予測- 国別分析

第10章過活動膀胱治療市場-業界情勢

第11章企業プロファイル

第12章付録